Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination
Authors
Keywords
-
Journal
CNS DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-11
DOI
10.1007/s40263-020-00756-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
- (2020) Robert T. Naismith et al. CNS DRUGS
- Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
- (2020) Damiano Paolicelli et al. CNS DRUGS
- A potential role for integrins in host cell entry by SARS-CoV-2
- (2020) Christian JA Sigrist et al. ANTIVIRAL RESEARCH
- Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
- (2020) Chuan Qin et al. CLINICAL INFECTIOUS DISEASES
- Immunology of COVID-19: current state of the science
- (2020) Nicolas Vabret et al. IMMUNITY
- A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia
- (2020) Isabella Quinti et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Clinical and immunological features of severe and moderate coronavirus disease 2019
- (2020) Guang Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- SARS-CoV-2: a storm is raging
- (2020) Savannah F. Pedersen et al. JOURNAL OF CLINICAL INVESTIGATION
- TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
- (2020) Dandan Wu et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection
- (2020) Marco Chiarini et al. JOURNAL OF NEUROIMMUNOLOGY
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- COVID-19: consider cytokine storm syndromes and immunosuppression
- (2020) Puja Mehta et al. LANCET
- Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression
- (2020) Tiziana Carandini et al. Multiple Sclerosis Journal
- Human neutralizing antibodies elicited by SARS-CoV-2 infection
- (2020) Bin Ju et al. NATURE
- The COVID-19 vaccine development landscape
- (2020) Tung Thanh Le et al. NATURE REVIEWS DRUG DISCOVERY
- Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic
- (2020) Wallace Brownlee et al. NEUROLOGY
- Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young
- (2020) Thomas J. Oxley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover
- (2020) Annarosa Soresina et al. PEDIATRIC ALLERGY AND IMMUNOLOGY
- The COVID-19 pandemic and the use of MS disease-modifying therapies
- (2020) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
- (2020) Bo Diao et al. Frontiers in Immunology
- Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
- (2020) Yonggang Zhou et al. National Science Review
- COVID-19 in MS
- (2020) James D. Bowen et al. Neurology-Neuroimmunology & Neuroinflammation
- Clinical exacerbation of SARS‐CoV2 infection after fingolimod withdrawal
- (2020) Victor Gomez‐Mayordomo et al. JOURNAL OF MEDICAL VIROLOGY
- COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
- (2020) Vittorio Mantero et al. JOURNAL OF NEUROLOGY
- Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse
- (2020) Nora Möhn et al. JOURNAL OF NEUROLOGY
- COVID-19 in teriflunomide-treated patients with multiple sclerosis
- (2020) Amir Hadi Maghzi et al. JOURNAL OF NEUROLOGY
- An Italian programme for COVID-19 infection in multiple sclerosis
- (2020) Maria Pia Sormani LANCET NEUROLOGY
- Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study
- (2020) Gloria Dalla Costa et al. NEUROLOGICAL SCIENCES
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis
- (2020) Céline Louapre et al. JAMA Neurology
- A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19
- (2020) Cristina Valencia-Sanchez et al. Multiple Sclerosis and Related Disorders
- COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach
- (2020) Giovanna Borriello et al. Multiple Sclerosis and Related Disorders
- Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
- (2020) Christian Foerch et al. Multiple Sclerosis and Related Disorders
- B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran
- (2020) Farinaz Safavi et al. Multiple Sclerosis and Related Disorders
- Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic
- (2020) Mahsa Ghajarzadeh et al. Multiple Sclerosis and Related Disorders
- Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain
- (2020) Paloma Montero-Escribano et al. Multiple Sclerosis and Related Disorders
- COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
- (2020) Richard Hughes et al. Multiple Sclerosis and Related Disorders
- COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
- (2020) Giovanni Novi et al. Multiple Sclerosis and Related Disorders
- Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
- (2020) Luca Bollo et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab
- (2020) Jorge Matías-Guiu et al. Multiple Sclerosis and Related Disorders
- COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
- (2020) Virginia Meca-Lallana et al. Multiple Sclerosis and Related Disorders
- Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab
- (2020) Carlos Guevara et al. Multiple Sclerosis and Related Disorders
- Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia
- (2020) William L Conte Multiple Sclerosis and Related Disorders
- Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
- (2020) Matteo Lucchini et al. Multiple Sclerosis and Related Disorders
- Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
- (2020) Jeanine Rempe Thornton et al. Multiple Sclerosis and Related Disorders
- Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
- (2020) Clara Aguirre et al. Multiple Sclerosis and Related Disorders
- MSCOVID19: Using social media to achieve rapid dissemination of health information
- (2020) Cassie Nesbitt et al. Multiple Sclerosis and Related Disorders
- Spontaneous multiple cervical artery dissections after alemtuzumab
- (2019) Françoise Durand-Dubief et al. Multiple Sclerosis Journal
- A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence
- (2019) Martin Diebold et al. Multiple Sclerosis Journal
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
- (2019) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy
- (2018) H. K. Olberg et al. EUROPEAN JOURNAL OF NEUROLOGY
- Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies
- (2018) Christoph Metze et al. CNS Neuroscience & Therapeutics
- Treatment of Theiler’s virus-induced demyelinating disease with teriflunomide
- (2017) Francesca Gilli et al. JOURNAL OF NEUROVIROLOGY
- Cladribine to Treat Relapsing Forms of Multiple Sclerosis
- (2017) Gavin Giovannoni Neurotherapeutics
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extended interval dosing of natalizumab in multiple sclerosis
- (2016) L Zhovtis Ryerson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease
- (2015) Darren M. Roberts et al. JOURNAL OF AUTOIMMUNITY
- Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis
- (2015) L. Kappos et al. NEUROLOGY
- Established and novel disease-modifying treatments in multiple sclerosis
- (2014) A. H. Cross et al. JOURNAL OF INTERNAL MEDICINE
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies
- (2014) Paolo Pellegrino et al. VACCINE
- Multiple sclerosis treatment and infectious issues: update 2013
- (2013) A. Winkelmann et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
- (2013) A. Bar-Or et al. NEUROLOGY
- Humoral immune response to influenza vaccine in natalizumab-treated MS patients
- (2012) Mattias Vågberg et al. NEUROLOGICAL RESEARCH
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
- (2011) Bernd C. Kieseier CNS DRUGS
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab
- (2009) Sander van Assen et al. ARTHRITIS AND RHEUMATISM
- The role of B lymphocytes as antigen-presenting cells
- (2008) Xinjian Chen et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More